The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1027
May 22, 1998
View Complete Issue         Table of Contents 2019 
Repaglinide for Type 2 Diabetes Mellitus
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Repaglinide for Type 2 Diabetes Mellitus
May 22, 1998 (Issue: 1027)
Repaglinide (Prandin - Novo Nordisk) is a new oral glucose-lowering agent for treating type 2 diabetes (formerly called non-insulin-dependent diabetes mellitus or NIDDM). It has been approved by the FDA for monotherapy or for use in combination with...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Repaglinide for Type 2 Diabetes Mellitus
Article code: 1027a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.